Keymed Biosciences

Executive Summary

Keymed Biosciences is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, that specializes in developing innovative antibody-based therapeutics for oncology and immunology. Leveraging its proprietary antibody discovery and engineering platforms, the company has built a pipeline of monoclonal and bispecific antibodies targeting a range of diseases. Lead candidates include CM310 (anti-IL-4Rα) for allergic conditions such as atopic dermatitis and asthma, which has advanced into late-stage clinical trials, and CMG901 (anti-Claudin18.2 antibody-drug conjugate) for solid tumors like gastric cancer. The company's deep expertise in antibody engineering and its diversified pipeline position it as a notable player in China's biotech landscape. With a focus on first-in-class and best-in-class molecules, Keymed aims to address significant unmet medical needs both domestically and globally. As a private company, Keymed has demonstrated strong execution by advancing multiple programs into Phase 2 and beyond. Its ability to generate compelling clinical data and secure strategic partnerships will be critical for future growth. The company's progress in the coming quarters is expected to be driven by key data readouts and potential licensing deals. Given its robust pipeline and the growing demand for innovative therapies in China, Keymed is well-positioned to capitalize on its R&D capabilities, though near-term catalysts remain tied to clinical milestones and business development activities.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for CM310 in atopic dermatitis75% success
• Q4 2026Initiation of Phase 3 trial for CMG901 in gastric cancer60% success
• H2 2026Potential licensing or partnership deal for CM326 (anti-TSLP)40% success